Pinotsis Nikos, Leonidas Demetres D, Chrysina Evangelia D, Oikonomakos Nikos G, Mavridis Irene M
Institute of Physical Chemistry, National Center for Scientific Research "Demokritos," Athens, Greece.
Protein Sci. 2003 Sep;12(9):1914-24. doi: 10.1110/ps.03149503.
A number of regulatory binding sites of glycogen phosphorylase (GP), such as the catalytic, the inhibitor, and the new allosteric sites are currently under investigation as targets for inhibition of hepatic glycogenolysis under high glucose concentrations; in some cases specific inhibitors are under evaluation in human clinical trials for therapeutic intervention in type 2 diabetes. In an attempt to investigate whether the storage site can be exploited as target for modulating hepatic glucose production, alpha-, beta-, and gamma-cyclodextrins were identified as moderate mixed-type competitive inhibitors of GPb (with respect to glycogen) with K(i) values of 47.1, 14.1, and 7.4 mM, respectively. To elucidate the structural basis of inhibition, we determined the structure of GPb complexed with beta- and gamma-cyclodextrins at 1.94 A and 2.3 A resolution, respectively. The structures of the two complexes reveal that the inhibitors can be accommodated in the glycogen storage site of T-state GPb with very little change of the tertiary structure and provide a basis for understanding their potency and subsite specificity. Structural comparisons of the two complexes with GPb in complex with either maltopentaose (G5) or maltoheptaose (G7) show that beta- and gamma-cyclodextrins bind in a mode analogous to the G5 and G7 binding with only some differences imposed by their cyclic conformations. It appears that the binding energy for stabilization of enzyme complexes derives from hydrogen bonding and van der Waals contacts to protein residues. The binding of alpha-cyclodextrin and octakis (2,3,6-tri-O-methyl)-gamma-cyclodextrin was also investigated, but none of them was bound in the crystal; moreover, the latter did not inhibit the phosphorylase reaction.
糖原磷酸化酶(GP)的一些调节性结合位点,如催化位点、抑制剂位点和新的别构位点,目前正在作为高葡萄糖浓度下抑制肝糖原分解的靶点进行研究;在某些情况下,特定抑制剂正在人体临床试验中进行评估,用于2型糖尿病的治疗干预。为了研究储存位点是否可作为调节肝葡萄糖生成的靶点,α-、β-和γ-环糊精被确定为GPb(相对于糖原)的中度混合型竞争性抑制剂,其抑制常数(K(i))值分别为47.1、14.1和7.4 mM。为了阐明抑制的结构基础,我们分别以1.94 Å和2.3 Å的分辨率测定了与β-和γ-环糊精复合的GPb的结构。这两种复合物的结构表明,抑制剂可以容纳在T态GPb的糖原储存位点中,三级结构变化很小,并为理解它们的效力和亚位点特异性提供了基础。将这两种复合物与与麦芽五糖(G5)或麦芽七糖(G7)复合的GPb进行结构比较,结果表明β-和γ-环糊精的结合模式类似于G5和G7的结合,只是其环状构象造成了一些差异。似乎酶复合物稳定的结合能来自与蛋白质残基的氢键和范德华接触。还研究了α-环糊精和八(2, ,6-三-O-甲基)-γ-环糊精的结合,但它们在晶体中均未结合;此外,后者也不抑制磷酸化酶反应。